EUVIMEDOpdag EUVIMED
Open access · CC BY-NC-ND 4.0

Release of Cell-Free Tumor DNA in the Plasma of Uveal Melanoma Patients Under Radiotherapy

Viktoria Kim, Maja Guberina, Nikolaos E Bechrakis, Dietmar R Lohmann, Michael Zeschnigk, Claudia H D Le Guin

Investigative Opthalmology & Visual Science · 2023

DOI: 10.1167/iovs.64.13.35 ↗

At a glance

Journal article in Investigative Opthalmology & Visual Science, 2023. Written by Viktoria Kim and 5 co-authors. Institution: Institute of Human Genetics, University Hospital Essen, University Duisburg-Essen, Essen, Germany. Major MEDLINE topics: Uveal Neoplasms, Circulating Tumor DNA. Cited 8 times so far (Crossref); 37 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Purpose

Uveal melanoma (UM) is a tumor of the eye that metastasizes in approximately half of cases. Prognostic testing requires accessibility to tumor tissue, which is usually not available with eye-preserving therapies. Noninvasive approaches to prognostic testing that provide valuable information for patient care are therefore needed. The aim of this study was to evaluate the use of circulating cell-free plasma DNA analysis in UM patients undergoing brachytherapy.

Methods

The study recruited 26 uveal melanoma patients referred to the department between February and October 2020. Blood samples were collected at various time points before, during, and after treatment, and deep amplicon sequencing was used to identify oncogenic variant alleles of the GNAQ and GNA11 genes, which serve as indicators for the presence of circulating tumor DNA (ctDNA).

Results

The results showed that all patients were ctDNA negative before brachytherapy. In 31% of patients, ctDNA was detected during therapy. The variant allele fraction of GNAQ or GNA11 alleles in ctDNA positive samples ranged from 0.24% to 2% and correlates with the largest basal diameter and thickness of the tumor.

Conclusions

The findings suggest that brachytherapy increases the presence of tumor DNA in the plasma of UM patients. Thus ctDNA analysis may offer a noninvasive approach for prognostic testing. However, efforts are still required to lower the limit of detection for tumor-specific genetic alterations.

Subjects

MeSH terms (MEDLINE)

Uveal NeoplasmsCirculating Tumor DNAGTP-Binding Protein alpha SubunitsMutationDNA Mutational AnalysisHumansDNA, NeoplasmGTP-Binding Protein alpha Subunits, Gq-G11MelanomaUveal Melanoma

Substances

Circulating Tumor DNAGTP-Binding Protein alpha SubunitsGTP-Binding Protein alpha Subunits, Gq-G11DNA, Neoplasm

Authors and institutions

  • Institute of Human Genetics, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
  • Department of Ophthalmology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
  • Department of Radiotherapy, University Hospital Essen, University Duisburg-Essen, Essen, Germany.

Cite

APA

Kim, V., Guberina, M., Bechrakis, N. E., Lohmann, D. R., Zeschnigk, M., & Le Guin, C. H. D. (2023). Release of Cell-Free Tumor DNA in the Plasma of Uveal Melanoma Patients Under Radiotherapy. Investigative Opthalmology & Visual Science. https://doi.org/10.1167/iovs.64.13.35

Vancouver

Kim V, Guberina M, Bechrakis NE, Lohmann DR, Zeschnigk M, Le Guin CHD. Release of Cell-Free Tumor DNA in the Plasma of Uveal Melanoma Patients Under Radiotherapy. Investigative Opthalmology & Visual Science. 2023. doi:10.1167/iovs.64.13.35

BibTeX
@article{Kim2023,
  author = {Kim, Viktoria and Guberina, Maja and Bechrakis, Nikolaos E and Lohmann, Dietmar R and Zeschnigk, Michael and Le Guin, Claudia H D},
  title = {Release of Cell-Free Tumor DNA in the Plasma of Uveal Melanoma Patients Under Radiotherapy},
  journal = {Investigative Opthalmology & Visual Science},
  year = {2023},
  doi = {10.1167/iovs.64.13.35}
}
Start for free →